Haemonetics Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.4B-0.6% YoYTTM through 27 Jun 2026
Net Income $96.3M-42.6% YoYTTM through 27 Jun 2026
Free Cash Flow $291.2MTTM through 27 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 59.0% |
| EBITDA Margin | 20.0% |
| Operating Margin | 11.7% |
| Net Margin | 7.1% |
Returns
12.2%ROE
4.1%ROA
5.4%ROIC
Balance Sheet Health
Debt / Equity1.54x
Current Ratio2.95x
Net Debt$979.1M
Cash & Equivalents$223.4M
Quality Metrics
Altman Z-Score3.20
Piotroski F-Score8 / 9
FCF Margin21.5%
Rule of 4026.2
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2026: $1.3B
Diluted EPS$2.07TTMFY2026: $2.05
Dividend
No dividend
Capital Allocation
R&D Spend$59.7M
Capex Intensity2.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Plasma | View detailsThe company is targeting opportunities in plasma and platelets, aligning with broader strategic objectives. | ||
| Blood Center | View detailsBlood Center operates in more challenging markets, and the company has sharpened its focus on targeted opportunities, particularly in plasma and platelets. | ||
| Hospital | View detailsThe company believes that Plasma and Hospital have the greatest growth potential and are well positioned to drive long-term value. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.